P. Taylor, M. Weinblatt, G. Burmester
May 25, 2019
Citations
3
Influential Citations
131
Citations
Quality indicators
Journal
Arthritis & Rheumatology (Hoboken, N.j.)
Abstract
To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately‐to‐severely active rheumatoid arthritis (RA).